Targeted Therapy for Colorectal Cancer - Advanced Cancer Care
Targeted Therapy for Colorectal Cancer
- •EGFR inhibitors(e.g., cetuximab, panitumumab) used particularly in RAS wild-type tumors
- •VEGF inhibitors(e.g., bevacizumab) that inhibit tumor blood vessel growth
- •BRAF inhibitors(e.g., encorafenib combined with cetuximab) in specific mutated cases
- •Emerging therapiestargeting HER2 amplification and immune checkpoints
Combination with chemotherapy regimens is common to improve effectiveness.
When Targeted Therapy is Indicated
- •After surgical resection (colectomy) and chemotherapyin advanced, metastatic, or high-risk colorectal cancer to improve survival
- •For locally advanced or metastatic colorectal cancerespecially when molecular testing identifies actionable genetic mutations.
Treatment Process
Targeted therapy is generally administered intravenously in outpatient settings across several sessions over weeks to months. The procedure is usually painless and commonly given alongside chemotherapy or immunotherapy.
Benefits and Risks
Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.
Benefits include improved progression-free and overall survival, a personalized treatment approach targeting tumor-specific mutations, and generally fewer systemic side effects versus traditional chemotherapy. Side effects can include rash, diarrhea, fatigue, hypertension, and infusion reactions; these are drug-specific and manageable with care.
Aftercare and Recovery
Post-treatment care entails monitoring side effects, routine follow-ups to assess response, and supportive lifestyle modifications. Prompt communication with the care team about new symptoms is vital.
Why Choose Everhope
Everhope Oncology offers advanced colorectal cancer targeted therapies with expert oncologists, cutting-edge genetic profiling, personalized treatment plans, access to newest approved agents, comprehensive education, and ongoing patient support.
FAQs
Drugs that target specific genetic mutations or proteins in cancer cells to halt growth.
EGFR, VEGF, BRAF inhibitors and newer agents.
Varies by drug, regimen, and location; insurance and government aid can reduce costs.
Skin issues, diarrhea, fatigue, hypertension, usually less severe than chemotherapy.
Typically given intravenously in sessions over weeks-months.
Improved survival, fewer side effects, personalized approach.
Yes, ongoing research brings new combination and ligand-targeted therapies.